Dr Sarah Zielsdorf speaks of LDN for Chronic Pain at the MD Custom RX event (Low dose naltrexone) from LDN Research Trust on Vimeo.

Low dose naltrexone in refractory neuropathic pain associated with autoimmune transverse myelitis

J Pain
01 April 2015
https://www.jpain.org/article/S1526-5900(15)00354-5/fulltext

A case of transverse myelitis (TM) with secondary central pain syndrome refractory to multiple pain medications and immune-modulation therapies, which responded to low dose (3-4.5 mg) Naltrexone.

Endogenous opioid inhibition of proliferation of T and B cell subpopulations in response to immunization for experimental autoimmune encephalomyelitis

BMC Immunol
24 April 2015
https://pubmed.ncbi.nlm.nih.gov/25906771/

Initial Findings of an Open-Label Trial of Low-Dose Naltrexone for Symptomatic Mesenteric Panniculitis

J Clin Gastroenterol
October 2015
https://www.academia.edu/28700218/Initial_Findings_of_an_Open_Label_Trial_of_Low_Dose_Naltrexone_for_Symptomatic_Mesenteric_Panniculitis

Low Dose Naltrexone (LDN): New in the treatment of chronic pain syndromes. What really matters – reduced pain or increased energy?

Neuro Sciences
15 October 2015
https://www.jns-journal.com/article/S0022-510X(15)01775-X/fulltext

No Antagonists for an Antagonist: One Pitfall of Chronic Oral Low-Dose Naltrexone

Pain Medicine
December 2015
http://www.painmedicinenews.com/download/Casespmnse1215_WM.pdf

A 48 year old man with 10 years of chronic abdominal pain following an open repair of an abdominal aortic aneurysm was treated with low dose naltrexone 1.5mg/day for 3 years with satisfactory results.

Off-Label, Low-Dose Naltrexone for Refractory Painful Diabetic Neuropathy

Pain Medicine
April 2016
http://painmedicine.oxfordjournals.org/content/early/2015/11/25/pm.pnv009

A novel glial cell inhibitor, low dose naltrexone, reduces pain and depression, and improves function in chronic pain: A CHOIR study

J Pain
01 April 2016
http://www.jpain.org/article/S1526-5900(16)00425-9/fulltext